Invest Ophthalmol Vis Sci
March 2019
Purpose: To identify protein mediators of corneal haze following presbyopic corneal inlay surgery.
Methods: Tears were collected from eyes with corneal haze following surgery with a shape-changing corneal inlay. Samples were subjected to quantitative proteomic analysis using iTRAQ and proteins significantly increased or decreased (1.
Purpose: To report the 9-12-month outcomes of a novel procedure for reduction of low myopia through epithelium-on photorefractive intrastromal cross-linking (PiXL) with customized control of topographic distribution of ultraviolet (UV)-fluence.
Method: Myopic patients with normal (non-ectatic) corneas underwent the PiXL procedure for reduction of low myopia. PiXL treatments were delivered through selective application of UVA light based on the refractive error of each patient.
Purpose: To establish a multidisciplinary surgical program for osteo-odonto-keratoprosthesis (OOKP) surgery in Asia and to evaluate efficacy and preliminary safety of this keratoprosthesis in end-stage corneal and ocular surface disease.
Design: Prospective noncomparative case series.
Participants: Sixteen adults of Asian ethnic origin, bilaterally blind with end-stage corneal blindness from Stevens-Johnson syndrome, or severe chemical or thermal burns.
Purpose: To report two cases of infectious keratitis occurring after laser epithelial keratomileusis (LASEK).
Methods: Two patients who underwent LASEK were referred to our center for the management of postoperative infectious keratitis. Infection occurred on postoperative days 2 (case 1) and 5 (case 2).
Objective: To describe a compressive lamellar surgical technique for treating severe astigmatism in peripheral corneal ectasia.
Design: Retrospective, noncomparative, interventional case series.
Participants: Four eyes of 3 patients with either pellucid or Terrien's marginal corneal degeneration were included in this series.
Invest Ophthalmol Vis Sci
November 2003
Purpose: To establish the safety and pharmacokinetic efficacy of an Oculex Drug Delivery System (DDS; Oculex Pharmaceuticals, Inc., Sunnyvale, CA) containing cyclosporin A (CsA) in the anterior segment of the rabbit eye.
Methods: The Oculex DDS is an intraocular, sustained-release, drug delivery system comprising a biodegradable lactic acid-glycolic acid copolymer.
Purpose: To present a series of 6 cases of microsporidial keratoconjunctivitis in healthy, nonimmunocompromised individuals.
Design: Retrospective, noncomparative case series.
Participants: Six individuals with unilateral keratoconjunctivitis.
J Ocul Pharmacol Ther
February 2002
The purpose of this study was to determine levels of cyclosporin A (CsA) in ocular tissues and fluids after oral or topical administration of CsA in humans requiring immunosuppression for penetrating keratoplasty and to evaluate the sensitivity of a high performance liquid chromatography coupled to electrospray mass spectrometry (LC-MS). High-risk penetrating keratoplasty was performed on 11 patients requiring 5 mg/kg of oral cyclosporin A and 9 patients with topical 0.5% (suspension, equivalent to 5 mg/ml)) preoperative immune suppression.
View Article and Find Full Text PDF